Arkolith/Insider Trading/RGNX/Form 4

Mills Kenneth T.

DirectorREGENXBIO Inc. (RGNX) · full profile →Form 4 · filed Jul 18, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$33K
Net Open-Market Flow
-$33K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 17, 2024Option exercise(M)2K$3.76$8K410K
Jul 17, 2024Sell(S)2K$13.77$30K408K
Jul 16, 2024Option exercise(M)200$3.76$752408K
Jul 16, 2024Sell(S)200$13.76$3K408K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 17, 2024Option exercise(M)2K—$079K
Jul 16, 2024Option exercise(M)200—$081K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-005798) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML